The challenge of preventing and treating a disease with great heterogeneity
DOI:
https://doi.org/10.47196/diab.v57i3.720Keywords:
type 1 diabetes mellitus, beta cell, teplizumabAbstract
Diabetes mellitus 1 (DM1) is an organ-specific autoimmune disease that results from the chronic immune-mediated destruction of insulin-producing β cells and affects more than 14 million people worldwide. It is a progressive process characterized by a preclinical phase of variable asymptomatic evolution, with the appearance of multiple autoantibodies that precede the development of dysglycemia and, subsequently, by a clinical phase with the typical cardinal symptoms that contribute to the diagnosis.
Although insulin was discovered a century ago and the development of new technologies to administer and monitor treatment has reduced the rate of complications and improved the quality of life of people with DM, the disease is still incurable. Patients require multiple daily injections or continuous insulin infusion systems to maintain acceptable blood glucose levels. And, despite these advances in intensive monitoring and treatment, most do not achieve metabolic objectives. The burden of living with DM is considerable for the patient, the family, and society.
References
I. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodríguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 fiabetes. N Engl J Med 2019 Aug 15; 381(7):603-613. doi: 10.1056/NEJMoa1902226.
II. Herold KC, Gitelman S, Gottlieb P, Knecht L, Raymond R, Ramos E. Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves b-cell function. Diabetes Care 2023;46(10):1-9. doi: 10.2337/dc23-0675.
III. Hollander NHM, Roep BO. From disease and patient heterogeneity to precision medicine in type 1 diabetes. Front Med 2022;9:932086. doi: 10.3389/fmed.2022.932086.
IV. Palmer JP. MD C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev 2009 May;25(4):325-328. doi:10.1002/dmrr.943.
V. Nagy G, Szekely T, Somogyi A , Herold M, Herold Z. New therapeutic approaches for type 1 diabetes: disease-modifying therapies. World J Diabetes 2022;13(10): 835-850. doi: 10.4239/wjd.v13.i10.835.
VI. Herold K, Gitelman S, Gottlieb P, Knecht L, Raymond R, Ramos E. Teplizumab: a disease-modifying therapy for type 1 diabetes that oreserves b-cell function. Diabetes Care 2023;46:1848-1856. doi: 10.2337/dc23-0675.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
